(Press-News.org) Contact information: Sandy Van
sandy@prpacific.com
808-526-1708
Cedars-Sinai Medical Center
Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 years
With standard care, median length of survival is 15 months after diagnosis of glioblastoma multiforme -- and only 10 percent survive more than 5 years
LOS ANGELES (NOV. 23, 2013) – Eight of 16 patients participating in a study of an experimental immune system therapy directed against the most aggressive malignant brain tumors – glioblastoma multiforme – survived longer than five years after diagnosis, according to Cedars-Sinai researchers, who presented findings Nov. 23 at the Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology.
Seven of the 16 participants still are living, with length of survival ranging from 60.7 to 82.7 months after diagnosis. Six of the patients also were "progression free" for more than five years, meaning the tumors did not return or require more treatment during that time. Four participants still remain free of disease with good quality of life at lengths ranging from 65.1 to 82.7 months following diagnosis. One patient who remained free of brain cancer for five years died of leukemia.
The original clinical trial – a Phase I study designed to evaluate safety – included 16 patients with glioblastoma multiforme enrolled between May 2007 and January 2010 by researchers at Cedars-Sinai's Johnnie L. Cochran, Jr. Brain Tumor Center.
Results published in January at the end of the study showed median overall survival of 38.4 months. Typically, when tumor-removal surgery is followed by standard care, which includes radiation and chemotherapy, median length of survival is about 15 months. Median progression-free survival – the time from treatment to tumor recurrence – was 16.9 months at study's end. With standard care, the median is about seven months.
The experimental treatment consists of a vaccine, ICT-107, intended to alert the immune system to the existence of cancer cells and activate a tumor-killing response. It targets six antigens involved in the development of glioblastoma cells.
According to information presented at the scientific meetings, all eight long-term survivors had tumors with at least five antigens, 75 percent had tumors with all six, and 100 percent had tumors with at least four antigens associated with cancer stem cells – cancer-originating cells that appear to enable tumors to resist radiation and chemotherapy and even regenerate after treatment.
"Our findings suggest that targeting antigens that are highly expressed by cancer stem cells may be a viable strategy for treating patients who have glioblastomas. Long-term remission of disease in this group of patients was correlated with the expression of cancer stem cell tumor-associated antigens," said Surasak Phuphanich, MD, director of the Neuro-Oncology Program at the Cochran Brain Tumor Center and professor of neurology with Cedars-Sinai's Department of Neurosurgery and Department of Neurology.
Based on results of the Phase I study, the ICT-107 vaccine entered a Phase II multicenter, randomized, placebo-controlled trial in 2011.
The vaccine is based on dendritic cells, the immune system's most powerful antigen-presenting cells – those responsible for helping the immune system recognize invaders. They are derived from white blood cells taken from each participating patient in a routine blood draw. In the laboratory, the cells are cultured with synthetic peptides of the six antigens – essentially training the dendritic cells to recognize the tumor antigens as targets. When the "new" dendritic cells in the vaccine are injected under the patient's skin, they are intended to seek and destroy lingering tumor cells. Vaccine is administered three times at two-week intervals after standard radiation and chemotherapy.
Phuphanich is first author of an abstract presented at the scientific meetings' poster session from 5 to 7 p.m. PST Nov. 23.
ICT-107 is a product of the biotechnology company ImmunoCellular Therapeutics, Ltd. Cedars-Sinai owns equity in the company, and certain rights in the dendritic cell vaccine technology and corresponding intellectual property have been exclusively licensed by Cedars-Sinai to ImmunoCellular Therapeutics, including rights associated with ICT-107, the vaccine investigated in this clinical study.
Several members of the research and presentation team have ties to the company. Abstract co-author Keith Black, MD, a Cedars-Sinai physician, owns stock in the company. Senior author John Yu, MD, a Cedars-Sinai physician, owns stock in the company and is its founder, chief scientific officer and chair of the board of directors. James Bender, PhD, MPH, a co-author, is Immunocellular Therapeutics' vice president for product development and manufacturing. Elma Hawkins, a co-author, also is identified with Immunocellular.
###
Co-authors who do not have relationships with the company include: Surasak Phuphanich, MD, PhD, first author; Christopher Wheeler, PhD; Jeremy Rudnick, MD; Jethro Hu, MD; Mia Mazer; Hong Q. Wang; Miriam Nuno; Cherry Sanchez; Xuemo Fan; Jianfel Ji; and Ray Chu, MD.
Citation: Abstract and poster presentation at Fourth Quadrennial Meeting of the World Federation of Neuro-Oncology, hosted by the Society for Neuro-Oncology, in San Francisco Nov. 21-24. Poster session from 5 to 7 p.m. PST Saturday, Nov. 23: "Long Term Remission Over 5 Years in Patients with Newly Diagnosed Glioblastoma (GBM) Treated with ICT-107 Vaccine: A Follow Up Study."
Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 years
With standard care, median length of survival is 15 months after diagnosis of glioblastoma multiforme -- and only 10 percent survive more than 5 years
2013-11-24
ELSE PRESS RELEASES FROM THIS DATE:
CVD expert calls for mandatory screening of 18 year-old Mexicans
2013-11-23
CVD expert calls for mandatory screening of 18 year-old Mexicans
Mexican diet more dangerous than fast food chains
Sophia Antipolis, France – 23 November 2013: A cardiovascular disease (CVD) expert is calling for mandatory screening of 18 year-old Mexicans ...
Sugar-sweetened beverage consumption increases endometrial cancer risk
2013-11-23
Sugar-sweetened beverage consumption increases endometrial cancer risk
PHILADELPHIA — Postmenopausal women who consumed sugar-sweetened beverages were more likely to develop the most common type of endometrial cancer compared with women who ...
Steroid injections for premature babies linked to mental health risk
2013-11-23
Steroid injections for premature babies linked to mental health risk
Steroid injections given to pregnant women before premature birth may increase the child's risk of later behavioural and emotional difficulties, a study has found.
Mothers who are expected ...
Acid raid, ozone depletion contributed to ancient extinction
2013-11-23
Acid raid, ozone depletion contributed to ancient extinction
Washington, D.C.— Around 250 million years ago, at the end of the Permian period, there was a mass extinction so severe that it remains the most traumatic known species die-off in Earth's history. ...
Greenland's shrunken ice sheet: We've been here before
2013-11-23
Greenland's shrunken ice sheet: We've been here before
Clues in the Arctic fossil record suggest that 3-5,000 years ago, the ice sheet was the smallest it has been in the past 10,000 years
BUFFALO, N.Y. — Think Greenland's ice sheet is small today?
It was smaller ...
'Wise chisels': Art, craftsmanship, and power tools
2013-11-23
'Wise chisels': Art, craftsmanship, and power tools
CAMBRIDGE, MA -- It's often easy to tell at a glance the difference between a mass-produced object and one that has been handcrafted: The handmade item is likely to have distinctive imperfections and ...
NASA's solar observing fleet to watch Comet ISON's journey around the sun
2013-11-23
NASA's solar observing fleet to watch Comet ISON's journey around the sun
It began in the Oort cloud, almost a light year away. It has traveled for over a million years. It has almost reached the star that has pulled it steadily forward for so ...
Study finds link between allergies and increased risk of blood cancers in women
2013-11-23
Study finds link between allergies and increased risk of blood cancers in women
Gender may play a role in the association of chronic immune stimulation and development of hematologic cancers
SEATTLE – A team of scientists looking into the interplay ...
Paths not taken: Notch signaling pathway keeps immature T cells on the right track
2013-11-23
Paths not taken: Notch signaling pathway keeps immature T cells on the right track
Implications for fighting T-cell leukemias
PHILADELPHIA - The lab of Avinash Bhandoola, PhD, professor of Pathology and Laboratory Medicine, has studied ...
Stuck on flu
2013-11-23
Stuck on flu
How a sugar-rich mucus barrier traps the virus -- and it gets free to infect
Researchers at the University of California, San Diego School of Medicine have shown for the first time how influenza A viruses snip through a protective mucus net ...
LAST 30 PRESS RELEASES:
Thirty-year mystery of dissonance in the “ringing” of black holes explained
Less intensive works best for agricultural soil
Arctic rivers project receives “national champion” designation from frontiers foundation
Computational biology paves the way for new ALS tests
Study offers new hope for babies born with opioid withdrawal syndrome
UT, Volkswagen Group of America celebrate research partnership
New Medicare program could dramatically improve affordability for cancer drugs – if patients enroll
Are ‘zombie’ skin cells harmful or helpful? The answer may be in their shapes
University of Cincinnati Cancer Center presents research at AACR 2025
Head and neck, breast, lung and survivorship studies headline Dana-Farber research at AACR Annual Meeting 2025
AACR: Researchers share promising results from MD Anderson clinical trials
New research explains why our waistlines expand in middle age
Advancements in muon detection: Taishan Antineutrino Observatory's innovative top veto tracker
Chips off the old block
Microvascular decompression combined with nerve combing for atypical trigeminal neuralgia
Cutting the complexity from digital carpentry
Lung immune cell type “quietly” controls inflammation in COVID-19
Fiscal impact of expanded Medicare coverage for GLP-1 receptor agonists to treat obesity
State and sociodemographic trends in US cigarette smoking with future projections
Young adults drive historic decline in smoking
NFCR congratulates Dr. Robert C. Bast, Jr. on receiving the AACR-Daniel D. Von Hoff Award for Outstanding Contributions to Education and Training in Cancer Research
Chimpanzee stem cells offer new insights into early embryonic development
This injected protein-like polymer helps tissues heal after a heart attack
FlexTech inaugural issue launches, pioneering interdisciplinary innovation in flexible technology
In Down syndrome mice, 40Hz light and sound improve cognition, neurogenesis, connectivity
Methyl eugenol: potential to inhibit oxidative stress, address related diseases, and its toxicological effects
A vascularized multilayer chip reveals shear stress-induced angiogenesis in diverse fluid conditions
AI helps unravel a cause of Alzheimer's disease and identify a therapeutic candidate
Coalition of Autism Scientists critiques US Department of Health and Human Services Autism Research Initiative
Structure dictates effectiveness, safety in nanomedicine
[Press-News.org] Update: 50 percent of patients in Cedars-Sinai brain cancer study alive after 5 yearsWith standard care, median length of survival is 15 months after diagnosis of glioblastoma multiforme -- and only 10 percent survive more than 5 years